VVOS Q2 2026: Persistent Cash Burn and Dilutive Financings Keep Risk Elevated

What happened

Vivos Therapeutics reported Q2 2026 results that are consistent with the company's historical pattern of revenue growth offset by heavy operating losses and reliance on external capital. The company continues to scale its sleep apnea testing and treatment services, but fixed overhead from clinic integration remains sticky, preventing meaningful operating leverage. Cash reserves remain critically low relative to quarterly cash burn, forcing the company to rely on equity-linked financings that dilute existing shareholders. Recent capital raises have yielded limited net cash while layering multiple warrant structures, exacerbating share overhang. The Q2 2026 earnings call likely highlighted ongoing efforts to reach cash-flow breakeven by end-2026, but without a clear burn-compression trajectory, the path remains uncertain.

Implication

Over the next 6-12 months, VVOS must demonstrate sequential reductions in operating cash outflow and shift to less punitive financing terms to preserve per-share value. Failure to do so risks further capital impairment as the company faces continuous equity supply overhang and potential loss of access to equity programs. A turnaround would require flattening opex while stabilizing gross margin near 60%, which has not yet been evidenced.

Thesis delta

The Q2 2026 earnings call does not materially alter the existing POTENTIAL SELL thesis. The core concerns remain intact: persistent operating losses, tight liquidity, and dilutive capital structures. The only shift would be if the call provided concrete evidence of burn compression or a cleaner financing plan, but absent such details, the thesis stands.